Portal de Periódicos da CAPES

Magnetic Resonance Imaging Contrast Enhancement of Brain Tumors at 3 Tesla Versus 1.5 Tesla

2002; Lippincott Williams & Wilkins; Volume: 37; Issue: 3 Linguagem: Inglês

10.1097/00004424-200203000-00003

1536-0210

I.-M. Nöbauer-Huhmann, Ahmed Ba‐Ssalamah, Vladimı́r Mlynárik, Markus Barth, ALEXANDER SCHÖGGL, K. Heimberger, Christian Matula, Amura Fog, Alexandra Kaider, Siegfried Trattnig,

Lanthanide and Transition Metal Complexes

Nöbauer-Huhmann IM, Ba-Ssalamah A, Mlynarik V, et al. Magnetic Resonance Imaging Contrast Enhancement of Brain Tumors at 3 Tesla Versus 1.5 Tesla. Invest Radiol 2002;37:114–119. rationale and objectives. To compare the diagnostic efficacy of a standard dose of MRI contrast agent in the evaluation of primary brain tumors and metastases using a high-field 3 tesla MR unit versus a 1.5 tesla MR unit. methods. Sixteen patients with brain tumors were examined at both field strengths using identical axial T1-SE protocols pre- and postcontrast (0.1 mmol/kg gadolinium), and postcontrast coronal 3D GRE with magnetization preparation (MP-RAGE), which was adjusted separately for each field strength. Evaluation of the images was performed quantitatively and, in the case of T1-SE images, also by visual assessment. results. Tumor-to-brain-contrast after gadolinium administration using statistical evaluation of MP-RAGE scans was significantly higher at 3 tesla (97.5) than at 1.5 tesla (46.3). The same was true for T1-SE sequences (93.0 vs. 72.1). Signal enhancement of the lesions in T1-SE sequences was not significantly different between both field strengths. conclusions. Administration of a gadolinium contrast agent produces higher contrast between tumor and normal brain at 3 tesla than at 1.5 tesla.